Click on headlines below to download research

The land of opportunity awaits Accrufer
Shield Therapeutics | 08/08/2019

Shield Therapeutics’ interim results highlight a momentous year to date, with the FDA approval of primary asset Feraccru/Accrufer, for the treatment…

FDA approval attained, sales execution now key
Shield Therapeutics | 26/07/2019

Shield Therapeutics’ primary asset, Feraccru, has been approved by the FDA for the treatment of iron deficiency in patients with any underlying cause…

Executive interview
Shield Therapeutics | 09/07/2019

Shield Therapeutics is a UK-based, speciality pharmaceutical company with a primary focus on commercialising its drug Feraccru, which is approved in Europe…

Next step US Feraccru approval
Shield Therapeutics | 03/04/2019

Shield Therapeutics reported FY18 results in line with our expectations. Total revenue of £11.9m included the £11.0m upfront payment from European…